Retrophin sells products to former CEO Martin Shkreli’s newco Turing Pharma
Executive Summary
Amid management and board shake-ups, including the replacement of its CEO Martin Shkreli, Retrophin Inc. (pediatric orphan and other diseases) scaled down its portfolio and sold Turing Pharmaceuticals LLC three non-core products for $3mm. Martin Shkreli, who also resigned from Retrophin’s board, founded Turing Pharmaceuticals to take over these assets.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
Drug Delivery
- Nasal
Deal Status
- Final
Deal Type
-
Alliance
- Intra-Biotech Deal
- Marketing (Licensing)
- Product Purchase
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice